Notably, preclinical studies have shown that AFP vaccination can activate antigen-specific T cell responses and enhance anti-tumor immunity (38), providing a rationale for exploring combination strategies with immune checkpoint inhibitors in AFP-positive HCC patients. The gene discussed is AFP; the disease is hepatocellular carcinoma.